10-QPeriod: Q1 FY1998

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 1998

Filed May 14, 1998For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed its quarterly report for the period ending March 30, 1998, on May 13, 1998. This filing provides a snapshot of the company's financial standing and operational activities during the first quarter of 1998. As a biotechnology company, Regeneron's performance is largely driven by its research and development pipeline and potential future product approvals. Investors will be keen to understand the progress in its drug development programs and any significant clinical trial updates or regulatory interactions. While specific financial figures and operational details are not provided in this extracted text, the filing's existence indicates ongoing business activities and reporting obligations, which are crucial for maintaining investor confidence and transparency.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. (REGN) filed its 10-Q quarterly report for the period ending March 30, 1998.
  • 2The filing was made on May 13, 1998, indicating timely reporting of its financial performance and business operations.
  • 3As a biotechnology firm, the report likely details progress in its research and development (R&D) pipeline, a critical factor for investors.
  • 4Investors would look for updates on clinical trials, potential drug candidates, and any significant scientific breakthroughs.
  • 5The filing serves as a key document for assessing the company's financial health and strategic direction during the first quarter of 1998.
  • 6The SEC filing process itself underscores Regeneron's status as a publicly traded company subject to regulatory oversight.

Frequently Asked Questions

This specific excerpt of the SEC filing does not detail the specific research and development programs. However, as a biotechnology company, Regeneron's R&D would typically focus on developing novel therapeutics for various diseases. Investors should consult the full 10-Q report for details on their pipeline, including specific drug candidates and therapeutic areas.

The provided text is a directory listing of the SEC filing and does not contain specific financial figures such as revenue, net income, or balance sheet details. To understand Regeneron's financial performance for the quarter ending March 30, 1998, the actual content of the 10-Q report (e.g., the financial statements section) would need to be reviewed.

The filing date of May 13, 1998, for the period ending March 30, 1998, indicates that Regeneron is adhering to its reporting deadlines with the Securities and Exchange Commission (SEC). This timely disclosure is important for maintaining transparency and providing investors with up-to-date information to make informed decisions.